Assuntos
Fármacos Dermatológicos , Isotretinoína , Prurido , Humanos , Prurido/induzido quimicamente , Prurido/tratamento farmacológico , Isotretinoína/efeitos adversos , Fármacos Dermatológicos/efeitos adversos , Masculino , Feminino , Acne Vulgar/tratamento farmacológico , Adulto , Antagonistas dos Receptores Histamínicos/uso terapêutico , Resultado do Tratamento , Adolescente , Adulto JovemRESUMO
BACKGROUND: Brief erythematous-papular skin rashes suggest the diagnosis of urticaria; However, it may be another type of dermatitis, and complementary examinations must be carried out to establish its diagnosis. CASE REPORT: 53-year-old female patient, diagnosed in 2016 with diffuse large B cell lymphoma, in complete remission. Since 2010, he has had episodes of erythematous-papular lesions lasting 24-36 hours. He received antihistamines, corticosteroids and omalizumab without clinical improvement. The ANA determination was positive (1/320), nuclear mitotic pattern. The skin biopsy was compatible with dermatitis herpetiformis. The study of celiac and locus antibodies showed positivity for HLA-DQ2 and DQ2.5 in heterozygosity. The diagnosis of dermatitis herpetiformis was established. Treatment consisted of a gluten-free diet and prescription of dapsone, with satisfactory results. CONCLUSION: It is important to establish the differential diagnosis of patients with chronic urticaria who do not respond to the reference treatment, in addition to carrying out a thorough clinical examination and physical examination before starting treatment and relying on a multidisciplinary team to establish an accurate diagnosis and treatment. appropriate. Due to the side effects of dapsone, subsequent follow-up of patients is essential.
ANTECEDENTES: Los exantemas cutáneos eritemato-papulares de breve duración sugieren el diagnóstico clínico de urticaria; no obstante, puede tratarse de otro tipo de dermatitis, y para establecer el diagnóstico deben llevarse a cabo exploraciones complementarias. REPORTE DE CASO: Paciente femenina de 53 años, diagnosticada en 2016 con linfoma difuso de células B grandes, en remisión completa. Desde el 2010 manifestó episodios de lesiones eritemato-papulosas, de 24-36 horas de duración. Recibió antihistamínicos, corticoides y omalizumab sin mejoría clínica. La determinación de ANA resultó positiva (1/320), con patrón mitótico nuclear. La biopsia cutánea fue compatible con dermatitis herpetiforme. El estudio de anticuerpos de celiaquía y locus mostró positividad para HLA-DQ2 y DQ2.5 con heterocigosis. Se estableció el diagnosticó de dermatitis herpetiforme. El tratamiento consistió en dieta exenta de gluten y prescripción de dapsona, con resultados satisfactorios. CONCLUSIÓN: Es importante establecer el diagnóstico diferencial de pacientes con urticaria crónica que no responden al tratamiento de referencia, además de efectuar el examen clínico y la exploración física exhaustivos antes de iniciar el protocolo, y apoyarse de un equipo multidisciplinario para establecer el diagnóstico certero y tratamiento adecuado. Debido a los efectos secundarios de la dapsona, es imprescindible el seguimiento posterior de los pacientes.
Assuntos
Urticária Crônica , Humanos , Pessoa de Meia-Idade , Feminino , Urticária Crônica/etiologia , Urticária Crônica/tratamento farmacológico , Urticária Crônica/diagnóstico , Dermatite Herpetiforme/diagnóstico , Dermatite Herpetiforme/etiologia , Dermatite Herpetiforme/complicações , Prurido/etiologia , Diagnóstico Diferencial , Dapsona/uso terapêuticoRESUMO
INTRODUCTION: Acquired perforating dermatosis (APD) is a frequent disorder in hemodialysis patients and the effect on the quality of life is poorly described. We investigated the prevalence of APD in hemodialysis patients, measured and compared APD-associated quality of life. METHODS: We developed a prospective, observational, and descriptive study. We invited patients over the age of 18 in hemodialysis. Data was obtained from their electronic file and a dermatological examination was performed. The Dermatology Life Quality Index (DLQI) was applied. Descriptive analysis of demographic variables, clinical features, and dermoscopy findings, as well as comparison of DLQI scores, was made. RESULTS: The sample consisted of 46 patients, with a prevalence of APD of 11%. Patients with APD were leaner and younger compared to patients without APD. The time on hemodialysis was longer in patients with APD compared to those without APD, with a median of 90 versus 32 months (pâ¯=â¯0.015). The impact on quality of life was greater in patients with APD compared to those without APD, with some effect in all patients with APD and 33% in patients without APD (pâ¯=â¯0.001). Patients with APD had more frequent pruritus compared to those without APD (pâ¯=â¯0.007). CONCLUSIONS: Age, time on hemodialysis and BMI are associated with the presence of APD. Patients with APD had a higher prevalence of pruritus and a greater impact on quality of life in dermatology compared to patients without APD.
Assuntos
Qualidade de Vida , Diálise Renal , Dermatopatias , Humanos , Masculino , Feminino , Estudos Prospectivos , Pessoa de Meia-Idade , Dermatopatias/etiologia , Dermatopatias/epidemiologia , Idoso , Prevalência , Prurido/etiologia , Prurido/epidemiologia , AdultoRESUMO
BACKGROUND: The treatment for atopic dermatitis (AD) has been the focus of clinical research, and behavioral intervention is considered an indispensable treatment method. To our knowledge, no relevant meta-analysis has evaluated the effects of behavioral interventions on atopic dermatitis. OBJECTIVES: To evaluate the effects of behavioral interventions on atopic dermatitis. METHODS: The authors searched PubMed, EMBASE, and Cochrane CENTRAL to retrieve relevant RCTs (up to Feb 2022). The search strategy involved a combination of related keywords. The Cochrane Q and I2 statistics were used to assess heterogeneity. RESULTS: Six RCTs involving seven reports with 246 patients were included. The results suggested that behavioral interventions could relieve eczema severity (correlation coefficient [r = -0.39]; pâ¯<â¯0.001) and scratching severity significantly (r = -0.19; pâ¯=â¯0.017), while not affect itching intensity (r = -0.02; pâ¯=â¯0.840). A sensitivity analysis confirmed the robustness of the results. STUDY LIMITATIONS: An important limitation of this study was the insufficient number of RCTs and the limited sample size. In addition, the study lacked a control group receiving a type of intervention other than the experimental protocol. Another limitation was the short duration of follow-up. CONCLUSIONS: This study suggests that behavioral interventions could be effective in treating atopic dermatitis by reducing eczema and scratching severity. Additionally, habit-reversal behavioral therapy may be more effective for treating atopic dermatitis.
Assuntos
Dermatite Atópica , Ensaios Clínicos Controlados Aleatórios como Assunto , Dermatite Atópica/terapia , Dermatite Atópica/psicologia , Humanos , Resultado do Tratamento , Índice de Gravidade de Doença , Terapia Comportamental/métodos , Prurido/terapia , Prurido/psicologia , FemininoRESUMO
OBJECTIVE: To evaluate the skin characteristics and quality of life of patients with breast cancer undergoing radiotherapy. METHOD: Cross-sectional study conducted with 60 women. The classification scales of skin changes resulting from exposure to ionizing radiation (RTOG) and the validated versions in Portuguese of those that classified skin types (Fitzpatrick), symptoms (RISRAS) and quality of life (DLQI) were applied. in the period between December 2021 and October 2022. For data analysis, Fisher's Exact Test, Chi-Square and Asymptotic General Independence Test were used. RESULTS: 100% of patients had skin irritation. As the treatment progressed and the radiodermatitis appeared or worsened, there was a tendency for the intensity of signs and symptoms to increase, such as: sensitivity, discomfort or pain, itching, burning and heat, dry and wet desquamation, which may have impacted the quality of life and reflected in other aspects, such as: shopping activities or outings (p=0.0020), social activities or leisure activities (p=0.0420). CONCLUSION: Radiodermatitis is a common condition that affects women with breast cancer undergoing radiotherapy, skin characteristics and quality of life of patients affected during this treatment.
Assuntos
Neoplasias da Mama , Radiodermite , Feminino , Humanos , Radiodermite/etiologia , Radiodermite/diagnóstico , Qualidade de Vida , Estudos Transversais , Neoplasias da Mama/radioterapia , PruridoRESUMO
Blepharitis is a very common disease in ophthalmology, dermatology and allergy practice. It generally follows a chronic course and is frequently associated with objective and/or subjective symptoms such as epiphora, red eye, dandruff, gritty sensation, itching, burning, photophobia, and blurred vision. The purpose of this study is to analyze the prevalence of Demodex spp. in patients with symptoms of chronic blepharitis. An analytical cross-sectional study was conducted in the period between 2016 and 2020. All patients with symptoms of chronic blepharitis who underwent a parasitological test of eyelashes (Rapitest) in the Dermatology Department of the Hospital Italiano de Buenos Aires were included. Those with previously established blepharitis due to another infectious cause were excluded. We analyzed 972 patients. Sixty percent (n=585) underwent a positive Rapitest for the presence of Demodex spp. Seventy five percent (n=728) were women. There were no significant differences in the prevalence associated with sex (p=0.38). Among the patients positive for Demodex spp., 65% (n=628) were older than 60 years old. The most frequently associated symptom was itching, present in 35% (n=342). A statistically significant decrease in the number of consultations was observed during the cold months of the year (May-June-July-August). Our results show a high prevalence of Demodex spp. in patients with chronic blepharitis. As its presence reveals a direct association with age, we recommend looking for this parasite in this age group.
Assuntos
Blefarite , Infestações por Ácaros , Ácaros , Animais , Humanos , Feminino , Pessoa de Meia-Idade , Masculino , Infestações por Ácaros/epidemiologia , Prevalência , Estudos Transversais , Blefarite/epidemiologia , Blefarite/parasitologia , Prurido/complicaçõesRESUMO
Background: Fixed erythema pigmento (FPE) is an allergic drug reaction, the pathophysiology of which is not exactly known. It is more common in women with location on the face. Clinical presentation: round or oval red-purple macule, well defined, with swelling, pain, itching, and burning. Diagnosis is clinical, oral chal- lenge is contraindicated due to possible severe reaction. On withdrawal of the drug, residual violaceous hyperpigmentation remains. Case report: 34-year-old female diagnosed with allergic rhinitis and asthma. She received treatment with ibuprofen and cephalexin 1 month ago due to dental infection. For the past 2 weeks, she has presented dermatological lesions characterized by hyperpigmentation under the lower eyelids, accompanied by pain, burning, and itching. On physical examination, well-defined red-purple pigmentation was observed in both periocular regions. The challenge test is not justified, the clinical history is the diagnostic pillar. The indication is to stop the medication immediately and continue monitoring. Conclusions: EPF is a drug reaction related to drug use. It creates a challenge for diagnosis due to poor knowledge of the characteristics of the dermatosis and poor clinical and pharmacological questioning. The EPF approach requires knowing the clinical characteristics of this dermatosis, making a differential diagnosis with other lesions and indicating the suspension of the responsible medication.
Antecedentes: El eritema pigmentado fijo (EPF) es una reacción alérgica medicamentosa, de la cual no se conoce con exactitud la fisiopatología. Es más frecuente en la mujer con localización en la cara. Presentación clínica: mácula redonda u oval de color rojo-violáceo, bien delimitada, con edema con dolor, prurito y ardor. El diagnóstico es clínico, contraindicado el reto oral por posible reacción grave. Al retirar el fármaco, queda una hiperpigmentación residual violácea. Reporte de caso: Femenina de 34 años con diagnóstico de rinitis alérgica y asma, Recibió tratamiento con Ibuprofeno y cefalexina hace 1 mes debido a proceso infeccioso dental. Desde hace 2 semanas presenta lesiones dermatológicas caracterizadas por hiperpigmentación debajo de párpados inferiores, acompañado de dolor, ardor y prurito. A la exploración física en ambas regiones perioculares se observa pigmentación bien delimitada rojo-violáceo. La prueba de reto no se justifica, la historia clínica es el pilar diagnóstico. La indicación es suspender el medicamento de inmediato y vigilancia continua. Conclusiones: El EPF es una reacción a medicamentos relacionada con el consumo de fármacos. Genera un desafío para el diagnóstico debido al pobre conocimien- to de las características de la dermatosis y un deficiente interrogatorio clínico y farmacológico. El abordaje del EPF requiere conocer las características clínicas de esta dermatosis, realizar el diagnostico diferencial con otras lesiones e indicar la suspensión del medicamento responsable.
Assuntos
Asma , Hiperpigmentação , Humanos , Feminino , Adulto , Hiperpigmentação/diagnóstico , Hiperpigmentação/patologia , Prurido/diagnóstico , Diagnóstico Diferencial , Asma/diagnósticoRESUMO
OBJECTIVE: To determine prevalence, causes and risk factors of ADE in hospitalized patients of a General Hospital. METHODS: Observational and analytical case-control study, carried out in patients hospitalized for adverse drug events, treated at the Hospital General Dr. Eduardo Vázquez N, in Puebla, Mexico, between, June 2019 to June 2021. For the statistical analysis, percentages, frequencies, means, odds ratio, χ2, and multiple binary logistic regression were used. Data were analyzed using the Statistical Package for the Social Sciences 23 program. RESULTS: A total of 132 patients (66 cases and 66 controls) were registered. Of the group of cases, 26 patients treated for medication error and 40 with adverse drug reaction were reported. The prevalence of adverse drug events was 3.6%. The drugs and factors associated with the most reported adverse events were: antibiotics, anti-inflammatories; average age of 35 years (SD: 17.41); gender: 39.3% men, 60.7% women; services re-ported with the greatest attention: Emergencies and Surgery; frequent route of administration: intravenous (32.3%); main symptoms: skin; symptoms associated with adverse drug reactions: type A pruritus [OR: 8.5, p = 0.001(CI95%: 0.035-0.393)], type B pruritus [OR: 11, p = 0.001 (CI95%: 0.021-0.368)]; urticaria [OR: 19, p = 0.005(CI95%: 0.007-0.412)]. Risk factors associated with adverse events were: female gender [OR: 2.6, p = 0.05 (CI95%: 1.33-5.43)], history of allergy [OR: 3.4, p = 0.033 (CI95%: 1.04-8.40)] and prolonged hospital stay [OR: 5.4, p = 0.023 (CI95%: 3.82-6.74)]. CONCLUSIONS: The majority of ADEs were EM or ADR type A, both preventable reactions, so patient safety should be a priority when prescribing.
OBJECTIVO: Determinar la prevalencia, causas y factores de riesgo en pacientes hospitalizados por eventos ad-versos a medicamentos. MÉTODOS: Estudio de casos y controles, observacional y analítico, llevado a cabo en pacientes hospitalizados por eventos adversos a medicamentos, atendidos en el Hospital General Dr. Eduardo Vázquez N, Puebla, México, entre junio de 2019 y junio de 2021. Para el análisis estadístico se utilizaron porcentajes, frecuencias, promedios, razón de momios, χ2 y regresión logística binaria múltiple. Los datos se analizaron con el programa Statistical Package, for the Social Sciencies 23. RESULTADOS: Se registraron 132 pacientes (66 casos y 66 controles). Del grupo de casos se informaron 26 pacientes atendidos por error de medicación y 40 con reacción adversa a medicamentos. La prevalencia de eventos adversos a medicamentos fue del 3.6%. Los medicamentos y factores asociados con eventos adversos más reportados fueron: antibióticos, antiinflamatorios; edad promedio de 35años (DE: 17.41); sexo: 39.3% hombres, 60.7% mujeres; servicios reportados con mayor atención: Urgencias y Cirugía; vía administración frecuente: intravenosa (32.3%); síntomas principales: cutáneos; síntomas asociados con reacciones adversas a medicamentos: tipo A prurito [RM: 8.5, p = 0.001(IC95%: 0.035-0.393)], tipo B prurito [RM:11, p = 0.001 (IC95%: 0.021-0.368)]; urticaria [RM: 19, p = 0.005(IC95%: 0.007-0.412)]. Los factores riesgo asociados con eventos adversos fueron: género femenino [RM: 2.6, p = 0.05 (IC95%: 1.33-5.43)], antecedente de alergia [RM: 3.4, p = 0.033 (IC95%: 1.04-8.40)] y estancia intrahospitalaria prolongada [RM: 5.4, p = 0.023 (IC95%: 3.82-6.74)]. CONCLUSIONES: La mayor parte de los eventos adversos a medicamentos se originan por errores de medicación o reacciones adversas a fármacos tipo A; sin embargo, ambos pueden prevenirse. La seguridad del paciente debe ser prioridad al momento de prescribir cualquier tipo de medicamento.
Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Urticária , Masculino , Humanos , Feminino , Adulto , Estudos de Casos e Controles , Prevalência , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia , Fatores de Risco , Hospitais Gerais , Prurido , HospitalizaçãoRESUMO
Studies on serum interleukin (IL)-31 levels in dogs with atopic dermatitis (AD) and their correlation with disease severity are limited. To the author's knowledge, there are no studies that measured serum IL-31 in dogs treated with lokivetmab injections, a selective inhibitor of this key cytokine in pruritus. The aim of the study was to evaluate serum IL-31 levels in dogs treated with lokivetmab and correlate it with the severity of canine atopic dermatitis using the pruritus visual analog scale (pVAS) and canine atopic dermatitis extent and severity index (CADESI-04). Ten client-owned dogs diagnosed with AD received two injections of lokivetmab four weeks apart. Disease severity was assessed using the pVAS and CADESI-04 scores before and after both injections. In addition, canine serum IL-31 levels were measured at the same moments. Serum IL-31 was detected in all dogs in the study. There was a significant reduction in pVAS scores and serum IL-31 after administrations. However, there was no difference in CADESI-04 scores, and there was no significant correlation between CADESI-04 scores and serum IL-31 in dogs diagnosed with AD. Nonetheless, a significant positive correlation was observed between the pVAS scores and serum IL-31 levels with lokivetmab therapy, which reinforces the role of IL-31 in the pathogenesis of pruritus in dogs with AD. The data presented here provide further evidence that IL-31 is directly involved in pruritus pathogenesis in dogs with AD. In addition, blocking IL-31 has a significant antipruritic effect, but has no influence on skin lesion severity and extension.